JP2010064984A - Dna synthase inhibitor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a DNA synthase inhibitor easily produced and having less adverse effects. <P>SOLUTION: Among carotenoid compounds, lutein, zeaxanthin and capsanthin are found out to inhibit the DNA synthase among the DNA metabolism system enzymes, especially restoration type DNA synthases selectively. Further, they are found to be effective as an inflammation and cell proliferation inhibitor. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

The present invention relates to a compound having a DNA synthase inhibitory action and use thereof. This compound can be used as a DNA synthase inhibitor, for example, as a research reagent, or as an anti-inflammatory agent, a cell growth inhibitor, an anticancer agent, or a lead compound thereof.

Eukaryotic DNA synthase (DNA polymerase) is involved in cell growth, division, differentiation, etc., α type is DNA replication, β type and λ type are repair and recombination, δ type and ε type Is known to have different functions depending on the type, such as both replication and repair, ζ to κ are responsible for repair, replication type (α, δ, ε), mitochondrial type (γ), and repair type (Β, δ, ε, ζ, η, θ, κ, λ, μ, σ, φ, poll-like-I, poll-like-II) (Non-Patent Documents 1 and 2).

Since DNA synthase is involved in cell growth and the like in this way, a DNA synthase inhibitor that inhibits the enzyme activity exhibits, for example, cancer cell growth inhibitory action against cancer and HIV against AIDS. It is considered that it exhibits an inhibitory effect on the derived reverse transcriptase and an immunosuppressive action that suppresses specific antibody production against an antigen against an immune disease. For this reason, development of pharmaceuticals effective for prevention and treatment of cancer diseases, viral diseases such as AIDS, and immune diseases using a DNA synthase inhibitor is expected.

For example, it has been reported that glycolipids having DNA synthase inhibitory activity are useful as anticancer agents, HIV-derived reverse transcriptase inhibitors, and immunosuppressants (Patent Documents 1 and 2). Currently, dideoxy TTP (ddTTP), N-methylmaleimide, butylphenyl-2′-deoxyguanosine-5′-triphosphate (dGTP) and the like are known as DNA synthase inhibitors (Non-patent Document 3). . These are problematic in that they are not easy to produce and that anticancer agents generally have strong side effects.

In addition, conventional anticancer agents have killed cancer cells, many of which have been generated, and have cancer cell growth-inhibiting action, but in recent years, development of anticancer agents for the purpose of preventing carcinogenesis has also been promoted. In this regard, as described in Patent Document 3, “initiator” and “promoter” are related in the step of canceration of normal cells, and canceration of normal cells is “(1) normal cells. Carcinogenesis that occurs through two steps: "2) the chromosomes of 2 are damaged by the initiator at the DNA level and are changed into potential tumor cells. (2) Promoters act on the potential tumor cells and change into tumor cells." The two-stage theory is becoming common. TPA (12-O-tetradecanoylphorbol-13-acetate) and the like are known as representatives of compounds having an action as a promoter, and carcinogenesis experiments using such tumor promoters are performed in cancer research. Searches for anti-tumor promoters that inhibit the action of such tumor promoters in the prevention of carcinogenesis and the search for anti-carcinogenic agents are ongoing.

In addition, when TPA is applied to the skin, it induces the production of inflammatory cytokine Interleukin-1α through the induction of Epidermal Ornithine Decarboxylase, Cycrooxygenase (COX) -2, and inducible Nitric oxide Synthase, and the production of active oxygen Increases and induces an inflammatory reaction, and induces edema and thickening (Non-patent Document 4).

Therefore, TPA not only induces chronic inflammation but also promotes cell growth as a tumor promoter, so it is considered that DNA synthase inhibitory activity, anti-inflammatory activity and anti-tumor promoter activity are related to each other. .

In recent years, the number of patients with inflammatory diseases such as atopic dermatitis, chemical hypersensitivity, and hay fever has increased and has become a social problem. Conventionally, steroidal drugs have been frequently used for inflammatory diseases such as dermatitis, and a certain therapeutic effect has been recognized. Recently, however, side effects caused by excessive use of steroids have become a problem. Aspirin and indomethacin, which are non-steroidal anti-inflammatory agents (NSAIDs), have serious side effects such as acute gastric ulcers when taken in large amounts.

JP-A-11-106395 JP 2000-143516 A JP-A-9-176184 U. Hubscher, G. Maga, S. Spadari, Eukaryotic DNA polymerases, Annu. Rev. Biochem. 71 (2002) 133-163. S. Kimura, Y. Uchiyama, N. Kasai, S. Namekawa, A. Saotome, T. Ueda, T. Ando, T. Ishibashi, M. Oshige, T. Furukawa, T. Yamamoto, J. Hashimoto, K. Sakaguchi, A novel DNA polymerase homologous to Escherichia coli DNA polymerase I from a higher plant, rice (Oryza sativa L.), Nucleic Acids Res. 30 (2002) 1585? 1592. Annual Review of Biochemistry, 2002, 71, 133-163 Carcinogenesis 28 (6), 2007, 1224-1231, Chung. Et al.

Accordingly, an object of the present invention is to provide a DNA synthase inhibitor that is easy to manufacture and has few side effects in view of the above-mentioned problems of conventional DNA synthase inhibitors, and further, to treat conventional inflammatory diseases. It is intended to solve the above problems of drugs and provide an inhibitor of inflammation with few side effects.

As a result of investigations to solve the above problems, the present inventor, among carotenoid compounds, in particular, lutein, zeaxanthin and capsanthin selectively select DNA synthase, particularly repair-type DNA synthase among DNA metabolizing enzymes. The present invention was completed by finding the inhibition.

Furthermore, it discovered that the said 3 compound has an anti-inflammatory action, and discovered the application as an inflammation inhibitor.

Furthermore, it discovered that it had anticancer action, and discovered the application as an anticarcinogen and an anticancer agent.

That is, the present invention provides a repair-type DNA synthase inhibitor containing as an active ingredient any one of lutein, zeaxanthin, and capsanthin.

The repair-type DNA synthase inhibitor of the present invention is particularly effective for β-type and λ-type.

The present invention also provides an inhibitor of inflammation caused by a repair-type DNA synthase containing any one of lutein, zeaxanthin, and capsanthin as an active ingredient.

The present invention also provides an inhibitor of cell growth caused by a repair-type DNA synthase containing lutein as an active ingredient.

The cell growth inhibitor of the present invention is particularly effective for cancer cells.

Furthermore, the cancer cells are particularly effective for colon cancer cells.

As described above, the present invention relates to the fact that lutein, zeaxanthin and capsanthin have a DNA synthase inhibitory action, as a DNA synthase inhibitor, as a biochemical reagent, and further as an inhibitor of inflammation and cell proliferation. It can be used for medicines and has various usefulness.

Hereinafter, specific embodiments and technical scope of the present invention will be described in detail.

A DNA synthase inhibitor has an inhibitory effect on cancer cell growth against cancer and inhibits HIV-derived reverse transcriptase against AIDS because DNA synthase is involved in cell growth, division and differentiation. It is considered to exhibit an action and an immunosuppressive action to suppress specific antibody production against an antigen against an immune disease. Therefore, the DNA synthase inhibitor of the present invention can be a food or drug effective for the prevention / treatment of viral diseases such as cancer and AIDS and immune diseases.

Further, since the DNA synthase inhibitor of the present invention has an action of suppressing inflammation, it can be used as an inhibitor of inflammation.

Specifically, the DNA synthase inhibitor of the present invention contains either lutein, zeaxanthin or capsanthin as an active ingredient.

The inventor's DNA synthase inhibitor is not limited to use as a DNA synthase selective inhibitor, but can be applied to pharmaceuticals and the like as an anticancer agent and an inflammation inhibitor. Can also be applied to pharmaceuticals and the like.

In the present invention, the “pharmacologically acceptable salt” includes hydrohalides such as hydrofluoride and hydrochloride, inorganic acid salts such as sulfate and nitrate, alkali metals such as sodium salt and potassium salt. Examples thereof include salts, sulfonates, organic acid salts, and amino acid salts. Preferred examples include hydrochlorides, sulfates, nitrates, sodium salts, and potassium salts.

Each compound of the present invention and a pharmacologically acceptable salt thereof may be natural products isolated and purified from plants or the like, or may be synthesized by a known synthesis method.

Utilization of the compound of the present invention as a lead compound in the drug development process includes use of the compound of the present invention as a lead compound in the drug development process. In addition, when the compound of the present invention is administered into the body, parenteral administration is preferable to oral administration, and it is preferable to encapsulate and administer it in a carrier such as a liposome. At this time, if a carrier that specifically recognizes cancer cells is used, the compound of the present invention can be efficiently transported to the target site (lesion site).

Further, the compound of the present invention can be used as a health food having an anticancer effect, an anticarcinogenic effect, or an anti-inflammatory effect by adding to and blended with foods and drinks in addition to the use in pharmaceuticals.

Next, a pharmaceutical composition and an edible composition comprising the compound of the present invention will be described. The anticancer agent and anti-inflammatory agent containing the compound of the present invention as an active ingredient can be administered to animals and humans as they are or as a pharmaceutical composition together with a conventional pharmaceutical preparation carrier. The dosage form of the pharmaceutical composition is not particularly limited and may be appropriately selected as necessary.For example, oral preparations such as tablets, capsules, granules, fine granules, powders, injections, Non-oral preparations such as suppositories are mentioned, and preferred examples include parenteral preparations.

In the present invention, oral preparations such as tablets, capsules, granules, fine granules, and powders are produced according to a conventional method using, for example, starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, inorganic salts, and the like. . The compounding amount of the compound of the present invention in these preparations is not particularly limited and can be appropriately designed. In addition to the compound of the present invention, a binder, a disintegrant, a surfactant, a lubricant, a fluidity promoter, a corrigent, a colorant, a fragrance and the like can be appropriately used for this type of preparation.

Examples of the binder include starch, dextrin, gum arabic powder, gelatin, hydroxypropyl starch, sodium methylcellulose, hydroxypropylcellulose, crystalline cellulose, ethylcellulose, polyvinylpyrrolidone, macrogol and the like. Examples of the disintegrant include starch, hydroxypropyl starch, carboxymethylcellulose sodium, carboxymethylcellulose calcium, carboxymethylcellulose, and low-substituted hydroxypropylcellulose. Examples of the surfactant include sodium lauryl sulfate, soybean lecithin, sucrose fatty acid ester, polyoxyethylene sorbitan fatty acid ester and the like. Examples of lubricants include talc, waxes, hydrogenated vegetable oils, sucrose fatty acid esters, magnesium stearate, calcium stearate, aluminum stearate, polyethylene glycol and the like. Examples of the fluidity promoter include light anhydrous silicic acid, dry aluminum hydroxide gel, synthetic aluminum silicate, magnesium silicate and the like. The compounds of the present invention can also be administered as suspensions, emulsions, syrups, and elixirs, and these various dosage forms may contain flavoring agents and colorants.

In order to express the desired effect of the present invention as a parenteral agent, it varies depending on the age, body weight, and degree of disease of the patient, but usually, 1 to 60 mg intravenously per day as the weight of the compound of the present invention in an adult, Intravenous infusion, subcutaneous injection, and intramuscular injection are suitable. This parenteral preparation is produced according to a conventional method, and generally used as diluent is distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn oil, propylene glycol, etc. it can. Furthermore, you may add a disinfectant, antiseptic | preservative, and a stabilizer as needed. In addition, from the viewpoint of stability, this parenteral preparation can be frozen after filling into a vial or the like, the water can be removed by ordinary freeze-drying treatment, and the liquid preparation can be re-prepared from the freeze-dried product immediately before use. Furthermore, you may add an isotonic agent, a stabilizer, an antiseptic | preservative, and a soothing agent as needed. The compounding quantity of the compound of this invention in these formulations is not specifically limited, It can set arbitrarily. Examples of other parenteral agents include liquid preparations for external use, coating agents such as ointments, suppositories for rectal administration, etc., and these are also produced according to conventional methods.

Another preferred embodiment of the composition of the present invention is an edible composition. That is, the compound of the present invention is used as it is as a liquid, gel or solid food, for example, juice, soft drink, tea, soup, soy milk, salad oil, dressing, yogurt, jelly, pudding, sprinkle, infant formula, cake. Add to mixes, powdered or liquid dairy products, bread, cookies, etc., and if necessary, process into pellets, tablets, granules etc. with excipients such as dextrin, lactose, starch, flavorings, pigments, etc. Further, it can be coated with gelatin or the like and molded into a capsule to be used as a health food or nutritional supplement.

Since the DNA synthase structure of humans and other mammals is almost the same, the DNA synthase inhibitor of the present invention can be used as a DNA synthase inhibitor derived from mammals other than humans.

Hereinafter, the present invention will be described in detail with reference to examples. However, the present invention is not limited to the following examples.

Since lutein (compound 1), zeaxanthin (compound 2) and capsanthin (compound 3) are all carotenoid compounds, as comparative examples, β-cryptoxanthin (compound 4), astaxanthin (compound 5), which are the same carotenoid compounds, are used. ), Canthaxanthin (compound 6) was used. All compounds were purchased from Sigma (St Luis, CA, UAS).

(Verification of DNA synthase inhibitory activity)
The activity of the carotenoid compounds 1-6 against the DNA synthase group was measured by the following method. Tests were conducted on mammalian DNA synthases α, β and λ as DNA synthases. DNA synthase α is a sample extracted and purified from bovine thymus by a conventional method, DNA synthase β is a rat-derived gene, DNA synthase λ is a human-derived gene, and a conventional gene recombination method is used. The preparations incorporated into Escherichia coli and produced were used.

In order to measure the inhibitory action of carotenoid compounds on these DNA synthases, a general DNA synthase reaction system (edited by the Japanese Biochemical Society, New Chemistry Experiment Course 2, Nucleic Acid IV, Tokyo Kagaku Dojin, pages 63-66) is used. It was. That is, a DNA synthesis reaction is carried out in a system containing [ ³ H] -TTP labeled with a radioisotope, and the radioactivity is used as an indicator of the amount of product (synthetic DNA chain).

The inhibition rate is (a) the amount of synthetic DNA in the control, and (b) the amount of synthetic DNA in the presence of the test substance.
(a-b) / a x 100 = inhibition rate (%)
As evaluated.

The obtained results are shown in Table 1 as the concentration of DNA synthesis inhibition 50% (50% inhibition concentration) (μM).

As shown in Table 1, Compound 1 (Lutein), Compound 2 (zeaxanthin), and Compound 3 (Capsanthin) selectively inhibited repair-type DNA synthases β and λ, not replication-type DNA synthase α. On the other hand, compounds 4-6 did not inhibit any DNA synthase. Compounds 1 to 3 inhibited not only human DNA synthase but also mouse-derived DNA synthase.

(Verification of anti-inflammatory and anti-carcinogenic effects)
TPA (12-O-tetradecanoylphorbol-13-acetate) not only induces chronic inflammation but also promotes cell growth in mammals as an oncogenic promoter. The present inventor believes that there is a relationship between a DNA synthase inhibitory action (particularly a DNA synthase lambda inhibitory activity involved in DNA repair and recombination), an anti-inflammatory action and an anti-tumor promoter activity. Thought. Therefore, it was examined whether carotenoid compounds 1 to 6 have anti-inflammatory activity.

Each inhibitory effect was calculated by measuring the weight of inflammatory edema induced by TPA after applying a predetermined amount of each compound to the mouse ear in advance. The test is basically performed according to the method described in Cancer Lett. 1984, 25, pp. 177-85, and 250 μg or 500 μg of the compound is applied to one ear of a mouse, and 30 minutes later, the same part and the opposite ear are applied. Apply 0.5 μg of TPA. After 7 hours, the weight of inflammatory edema induced by TPA was measured, and each inhibitory effect was calculated by comparing with the control (opposite ear).

The results are shown in Table 2 below.

As shown in Table 2, Compound 1 (Lutein), Compound 2 (zeaxanthin), and Compound 3 (capsanthin) suppressed inflammation depending on the coating amount. Despite astaxanthin, zeaxanthin and lutein having similar antioxidant capacity (Invest Ophthalmol Vis Sci, 44, 2003, E-Abstract 1699. Santocono, et al.), It is prominent in lutein and zeaxanthin Therefore, these compounds have an action of suppressing inflammation caused by DNA synthase. Furthermore, it is considered to have an anti-tumor promoter activity (in other words, an anti-carcinogenic activity) that suppresses the action of the tumor promoter TPA.

(Verification of cytostatic activity)
The cancer cell proliferation inhibitory effect of carotenoid compounds 1-6 was evaluated using the following method. The cells used in this experiment are human colon cancer-derived HCT116 cells. As the medium, DMEM medium (manufactured by Nippon Pharmaceutical Co., Ltd.) supplemented with fetal bovine serum 10% (v / v) and penicillin-streptomycin 5% (v / v) was used. Culturing was performed at 37 ° C. with 5% CO 2 incubation.

Compounds 1 to 6 were dissolved in the medium shown above in advance so as to obtain each test concentration. However, since all carotenoid compounds are poorly soluble in water, they were once dissolved in DMSO (dimethyl sulfoxide) and dissolved in the above medium. The final concentration of DMSO present in the medium is 0.1% in all test groups, and the possibility that DMSO is involved in the suppression of the growth of each cell used in this measurement example can be denied.

The culture for this experiment was performed in a 96-well microplate. Each well was seeded with 5.0 × 10 ³ cells and given 3 wells for one test concentration. Each cell was cultured in a plate for 24 hours, and after adding each concentration of compounds 1 and 2, it was cultured at 37 ° C. for 48 hours in a 5% CO 2 incubation, and the cell viability of each test group was determined. The determination of viability was performed using the living cell count reagent SF (the method of Talanta 1997, 44). The tetrazolium salt WST-8 contained in the living cell measurement reagent SF is reduced by intracellular dehydrogenase to produce highly sensitive water-soluble formazan. By directly measuring the absorbance of this formazan at 450 nm, live cells can be easily obtained. The number can be measured. Therefore, in this experiment, after culturing for 48 hours, the living cell number measuring reagent SF was added, and after further culturing for 2 hours, the absorbance (OD) at 450 nm was measured, and the cell viability was calculated by the following formula.

Cell viability (%) = (OD of test group−OD of medium-only well) ÷ (OD of control group−OD of well of medium only)

The obtained results are shown in FIG. This data is shown as the mean and standard deviation of 3 wells.

It has been shown that only Compound 1 (Lutein) significantly inhibits the growth of human colon cancer cells and can be used as a cell growth inhibitor, particularly an anticancer agent.

As described above, lutein, zeaxanthin and capsanthin are not limited to use as DNA synthase inhibitors, but can be applied to pharmaceuticals and the like as inhibitors of inflammation and cell proliferation.

It is a result of the growth inhibitory activity of the human colon cancer cell of the carotenoid compounds 1-6.

Claims (5)

An inhibitor of repair-type DNA synthase, which contains any one of lutein, zeaxanthin, and capsanthin as an active ingredient. An inhibitor of inflammation caused by a repair-type DNA synthase, which contains any one of lutein, zeaxanthin, and capsanthin as an active ingredient. An inhibitor of cell proliferation caused by repair-type DNA synthase containing lutein as an active ingredient. The inhibitor according to claim 3, wherein the cell is a cancer cell. The inhibitor according to claim 4, wherein the cancer cell is a colon cancer cell.

Images